Abbott Laboratories
ABT
Market Cap$184.33B
Close$
Earnings Call Q2 2024
July 18, 2024 - AI Summary
Abbott reported strong second quarter results with organic sales growth of over 9%, excluding COVID testing sales, and adjusted earnings per share of $1.14.
The company raised its full-year guidance, now forecasting organic sales growth of 9.5% to 10% and adjusted earnings per share in the range of $4.61 to $4.71.
Growth was led by double-digit growth in medical devices and high single-digit growth in established pharmaceuticals and nutrition.
Exclusive for Stockcircle Pro members
Sign up
$158.46
36.1% upside
Current Fair Value
36.1% upsideUndervalued by 36.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $184.33 Billion |
|---|---|
| Enterprise Value | $192.70 Billion |
| Dividend Yield | $2.1439 (2.02%) |
| Earnings per Share | $3.22 |
| Beta | 0.32 |
| Outstanding Shares | 1,739,633,759 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 32.74 |
|---|---|
| PEG | -616.7 |
| Price to Sales | 5.06 |
| Price to Book Ratio | 2.84 |
| Enterprise Value to Revenue | 4.73 |
| Enterprise Value to EBIT | 32.14 |
| Enterprise Value to Net Income | 34 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | 0.21 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Abbott Laboratories
CEO: Robert Ford